ALKS (Alkermes)
All Pro Portfolios with ALKS

People owning ALKS also tend to own:: ADCTAKAMARAYARRSAVIDAVNXBEAS

All Do-It-Yourself Portfolios with ALKS
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:Trading Nymph

Date:12 30 08

9:30

Not yet rated
Rate now:

By:sarah z

Date:07 09 08

Alkermes reversed its position from last month and said it will see a profit in fiscal 2009 after receiving a payment from Eli Lilly & Co.

Eli Lilly will pay the company $25.5 million, the remainder from its development partnership on AIR inhaled insulin. An additional $15.5 million had been paid during the fiscal 2008 fourth quarter.

Indianapolis-based Eli Lilly ended that program in February, citing expectations for a tough regulatory process and a weak market if approved. Pfizer Inc. made the only inhaled insulin to reach the market, but discontinued the product last year because of lagging sales.

Cambridge, Mass.-based Alkermes now expects profit between 11 cents and 16 cents per share on revenue between $200 million and $225 million, up from prior guidance for a loss of 11 cents to 16 cents per share on revenue between $175 million and $200 million.

Analysts polled by Thomson Financial expect, on average, a loss of 10 cents per share on revenue of $194.9 million.

In May, Alkermes had forecast a fiscal 2009 loss, as it cut 150 jobs and closed a manufacturing plant in Chelsea, Mass. in the wake of the AIR inhaled insulin decision. But, the company remains partners with Eli Lilly and Amylin Pharmaceuticals Inc. on Exenatide LAR, a longer-lasting version of the diabetes drug Byetta.

Neponse Equity Research analyst Noelle Tune, for Soleil Securities Group Inc., reaffirmed a "Buy" rating with a $17 price target on the stock, and said the company is likely to dodge full-year losses going forward.

"Of note, while additional minor payments from Eli Lilly may trickle in over the coming months, we expect this $25.5 million payment, along with ALKS receiving (patent) rights to the Chelsea facility, to close the chapter on AIR Insulin," Tune said, in a note to investors.

Alkermes has also expanded its stock buyback program by $40 million to $215 million.

Meanwhile, Cowen and Co. analyst Ian Sanderson reaffirmed a "Neutral" rating on the stock, citing the competitive risks for the company's two most anticipated programs; Exenatide LAR and Risperdal Consta, a long-acting form of the schizophrenia drug made by Johnson & Johnson. That partnership is Alkermes' most lucrative.

"Longer-term, Alkermes shares do have attractive upside potential, but appreciation will require that Byetta (Exenatide) LAR royalties more than compensate for the expected erosion of the Risperdal Consta royalty stream," he said in a note to investors.

Alkermes is also developing Vivitrol as an alcohol dependence treatment.

Not yet rated
Rate now:

By:sarah z

Date:07 02 08

Alkermes reversed its position from last month and said it will see a profit in fiscal 2009 after receiving a payment from Eli Lilly & Co.

Eli Lilly will pay the company $25.5 million, the remainder from its development partnership on AIR inhaled insulin. An additional $15.5 million had been paid during the fiscal 2008 fourth quarter.

Indianapolis-based Eli Lilly ended that program in February, citing expectations for a tough regulatory process and a weak market if approved. Pfizer Inc. made the only inhaled insulin to reach the market, but discontinued the product last year because of lagging sales.

Cambridge, Mass.-based Alkermes now expects profit between 11 cents and 16 cents per share on revenue between $200 million and $225 million, up from prior guidance for a loss of 11 cents to 16 cents per share on revenue between $175 million and $200 million.

Analysts polled by Thomson Financial expect, on average, a loss of 10 cents per share on revenue of $194.9 million.

In May, Alkermes had forecast a fiscal 2009 loss, as it cut 150 jobs and closed a manufacturing plant in Chelsea, Mass. in the wake of the AIR inhaled insulin decision. But, the company remains partners with Eli Lilly and Amylin Pharmaceuticals Inc. on Exenatide LAR, a longer-lasting version of the diabetes drug Byetta.

Neponse Equity Research analyst Noelle Tune, for Soleil Securities Group Inc., reaffirmed a "Buy" rating with a $17 price target on the stock, and said the company is likely to dodge full-year losses going forward.

"Of note, while additional minor payments from Eli Lilly may trickle in over the coming months, we expect this $25.5 million payment, along with ALKS receiving (patent) rights to the Chelsea facility, to close the chapter on AIR Insulin," Tune said, in a note to investors.

Alkermes has also expanded its stock buyback program by $40 million to $215 million.

Meanwhile, Cowen and Co. analyst Ian Sanderson reaffirmed a "Neutral" rating on the stock, citing the competitive risks for the company's two most anticipated programs; Exenatide LAR and Risperdal Consta, a long-acting form of the schizophrenia drug made by Johnson & Johnson. That partnership is Alkermes' most lucrative.

"Longer-term, Alkermes shares do have attractive upside potential, but appreciation will require that Byetta (Exenatide) LAR royalties more than compensate for the expected erosion of the Risperdal Consta royalty stream," he said in a note to investors.

Alkermes is also developing Vivitrol as an alcohol dependence treatment.

Not yet rated
Rate now:

By:sarah z

Date:06 25 08

Alkermes reversed its position from last month and said it will see a profit in fiscal 2009 after receiving a payment from Eli Lilly & Co.

Eli Lilly will pay the company $25.5 million, the remainder from its development partnership on AIR inhaled insulin. An additional $15.5 million had been paid during the fiscal 2008 fourth quarter.

Indianapolis-based Eli Lilly ended that program in February, citing expectations for a tough regulatory process and a weak market if approved. Pfizer Inc. made the only inhaled insulin to reach the market, but discontinued the product last year because of lagging sales.

Cambridge, Mass.-based Alkermes now expects profit between 11 cents and 16 cents per share on revenue between $200 million and $225 million, up from prior guidance for a loss of 11 cents to 16 cents per share on revenue between $175 million and $200 million.

Analysts polled by Thomson Financial expect, on average, a loss of 10 cents per share on revenue of $194.9 million.

In May, Alkermes had forecast a fiscal 2009 loss, as it cut 150 jobs and closed a manufacturing plant in Chelsea, Mass. in the wake of the AIR inhaled insulin decision. But, the company remains partners with Eli Lilly and Amylin Pharmaceuticals Inc. on Exenatide LAR, a longer-lasting version of the diabetes drug Byetta.

Neponse Equity Research analyst Noelle Tune, for Soleil Securities Group Inc., reaffirmed a "Buy" rating with a $17 price target on the stock, and said the company is likely to dodge full-year losses going forward.

"Of note, while additional minor payments from Eli Lilly may trickle in over the coming months, we expect this $25.5 million payment, along with ALKS receiving (patent) rights to the Chelsea facility, to close the chapter on AIR Insulin," Tune said, in a note to investors.

Alkermes has also expanded its stock buyback program by $40 million to $215 million.

Meanwhile, Cowen and Co. analyst Ian Sanderson reaffirmed a "Neutral" rating on the stock, citing the competitive risks for the company's two most anticipated programs; Exenatide LAR and Risperdal Consta, a long-acting form of the schizophrenia drug made by Johnson & Johnson. That partnership is Alkermes' most lucrative.

"Longer-term, Alkermes shares do have attractive upside potential, but appreciation will require that Byetta (Exenatide) LAR royalties more than compensate for the expected erosion of the Risperdal Consta royalty stream," he said in a note to investors.

Alkermes is also developing Vivitrol as an alcohol dependence treatment.

Not yet rated
Rate now:

By:Carlos Warter

Date:11 21 07

own

Not yet rated
Rate now:

By:josephviju

Date:07 03 07

DRUNK !!

Not yet rated
Rate now:

By:Jaime Gracia

Date:06 04 07

AIR® Insulin

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Downgraded by WR Hambrecht from Buy to Hold

Not yet rated
Rate now:

By:HASTYPUDEN

Date:02 13 07

NEW DRUGS

Not yet rated
Rate now:

By:MJC

Date:02 09 07

Another delivery name, will garner positive emotion as it marches toward its own inhaled insulin. Many products under development, many relationships w/majors. Good balance sheet. Cheap stock. Recent Q is cathartic

Not yet rated
Rate now:

Why I Hate This Stock

Comments not available
Add Your Comments  
Stock ALKS
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Squeezing the Shorts: Large-Cap ...

By Jonas Elmerraji Posted on Nov. 11, 2009 Recently we put our short-squeeze focus on smaller stocks; this week we’re going large-cap. With higher trading volumes, mo...

11.11.09 | 15:19 PM
Dividend Stocks for the Week

By Jonas Elmerraji Posted on Nov. 10, 2009 After six straight days of gains, the markets are taking a breather today, which gives us the chance to focus our attention b...

11.10.09 | 15:04 PM
This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Nov. 9, 2009 Financial-Services Bull: Barron’s talks with Anton Schutz, portfolio manager at the Burnham Financial Industries Fund (BURFX)...

11.09.09 | 11:01 AM
Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 9, 2009 Last week brought investors a welcome return to gains as the S&P 500 pushed up 3.2% over the course of the last five trading d...

11.09.09 | 08:04 AM
more articles
today 's lists
52-Week Highs

Here are some of the biggest stocks that made the 52-week high list on Nov. 2, 2009. more

Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more

Rising on Unusual Volume

Here are some stocks that moved up on unusual volume on Nov. 2, 2009. more